A Treatable CNP infection leads to development of Pathological Calcification & Inflammation in CAD

http://newmedia.ufm.edu/maniscalconanobacterium

Our principal cardiology investigator, Benedict Maniscalco, MD, FACC in a lecture on the development of pathological calcification in CAD. Dr. Maniscalco was the lead investigator for my NanobacTX clinical trial some years ago....the study was published in a cardiology journal. Please feel free to email me if any questions: info@nanobiotech.us or visit the website to read all of the basic science studies and clinical trial results on NanobacTX.

NanobacTX was shown to reverse CAD plaque volume, improve cardiac symptom surveys, improve exercise tolerance, improve lipid profile by lowering VLDL+LDL and raising HDL......and decrease CAC as objectively measured by well-controlled serial CAC scores.....

Read the full published studies, patient + physician testamonials and arrange for NanobacTX for your patients at our website: http://www.nanobiotech.us